<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/57AFEC13-8F7A-4039-85DA-8D08B64F1CC6"><gtr:id>57AFEC13-8F7A-4039-85DA-8D08B64F1CC6</gtr:id><gtr:name>FAPEMIG</gtr:name><gtr:address><gtr:line1>R. Raul Pompeia</gtr:line1><gtr:line2>101 Sao Pedro</gtr:line2><gtr:line3>Belo Hozinte - MG Cep: 30.330-080</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>School of Public Health</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/57AFEC13-8F7A-4039-85DA-8D08B64F1CC6"><gtr:id>57AFEC13-8F7A-4039-85DA-8D08B64F1CC6</gtr:id><gtr:name>FAPEMIG</gtr:name><gtr:address><gtr:line1>R. Raul Pompeia</gtr:line1><gtr:line2>101 Sao Pedro</gtr:line2><gtr:line3>Belo Hozinte - MG Cep: 30.330-080</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/18273C65-9566-4CC2-82F3-E11366F73B02"><gtr:id>18273C65-9566-4CC2-82F3-E11366F73B02</gtr:id><gtr:firstName>Silvio Santana</gtr:firstName><gtr:surname>Dolabella</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6419DCC8-A82D-4297-A17E-786F44F3F56F"><gtr:id>6419DCC8-A82D-4297-A17E-786F44F3F56F</gtr:id><gtr:firstName>VITOR</gtr:firstName><gtr:otherNames>LUIS</gtr:otherNames><gtr:surname>MATI</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0407F0FD-DC52-4936-841B-55B2D834E326"><gtr:id>0407F0FD-DC52-4936-841B-55B2D834E326</gtr:id><gtr:firstName>Stefan</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Geiger</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/731E5529-095B-4B41-8482-ED613EEE121C"><gtr:id>731E5529-095B-4B41-8482-ED613EEE121C</gtr:id><gtr:firstName>Michelle Nan</gtr:firstName><gtr:surname>Clements</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/96B93267-5CBE-4095-8348-A36D378F916E"><gtr:id>96B93267-5CBE-4095-8348-A36D378F916E</gtr:id><gtr:firstName>Karina</gtr:firstName><gtr:surname>Karina</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/35C0FCB1-93C4-4EB1-9AC7-9E09F1F27201"><gtr:id>35C0FCB1-93C4-4EB1-9AC7-9E09F1F27201</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>Fenwick</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7F7D6BDD-AED3-49D5-80FE-02CCAE1BDAFC"><gtr:id>7F7D6BDD-AED3-49D5-80FE-02CCAE1BDAFC</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:surname>Phillips</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B6F5ACF6-B741-4751-9537-0E652C792463"><gtr:id>B6F5ACF6-B741-4751-9537-0E652C792463</gtr:id><gtr:firstName>Pedro Henrique</gtr:firstName><gtr:surname>Gazzinelli Guimar?es</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FN017722%2F1"><gtr:id>CC36C3D2-F4C9-4A77-8BF1-A715F78F015F</gtr:id><gtr:title>Optimizing strategies to diagnose and control intestinal Schistosomiasis in low and moderate endemicity areas of Brazil</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/N017722/1</gtr:grantReference><gtr:abstractText>Over 200 million people suffer with the disease Schistosomiasis which is caused by the presence in the human blood vessels of trematode worms of the genus Schistosoma. This leads to long term disability and can be fatal. Therefore, intestinal and urinary schistosomiasis are considered serious public health problems in vast regions of Africa, Asia and Latin America. The current mainstream diagnostic method for intestinal schistosomiasis is the detection of eggs in stool by Kato-Katz. This method, however, is limited costly, time-consuming, and may be particularly unreliable where there is low levels of infection, as would be expected after several rounds of treatment or in regions where transmission is low. In order to overcome some of the pitfalls of this diagnostic method, there has been interest in developing new and more sensitive tests for the diagnosis of schistosomiasis. 

Antigen detection in urine (CCA) has been documented to be a sensitive and specific alternative to Kato-Katz in several moderate and high endemnicity settings. Data comparing the performance of stool microscopy (Kato-Katz) and a urine dipstick (CCA) in low Schistosomiasis prevalence settings, however, is currently lacking. In this context, the aim of this project is to compare the performance of CCA with Kato-Katz in the low endemic area of Minas Gerais State, and in a moderate endemic area of Sergipe State Brazil. 

Furthermore, the study aims to enhance knowledge of the spatial distribution of schistosomiasis in Brazil that will assist planning of the preventive chemotherapy strategy for the national schistosomiasis control programme.</gtr:abstractText><gtr:technicalSummary>Current diagnostic methods for intestinal schistosomiasis (detection of eggs in stool by Kato-Katz (KK)) are limited and may be particularly unreliable at low levels of infection, as would be expected after several rounds of treatment or in regions where transmission is low. In order to overcome some of the pitfalls of the KK method, there has been interest in developing new, more sensitive tests for the diagnosis of schistosomiasis. Antigen detection in urine (CCA) has been documented to be a sensitive and specific alternative to KK in several moderate and high endemnicity settings. Specific data comparing the performance of microscopy and antigen detection tests in low Schistosomiasis prevalence settings, however, is currently lacking. In this context, the primary aim of this project is to compare the performance of CCA with KK in the low endemic area of Minas Gerais State, and in a moderate endemic area of Sergipe State Brazil. An additional diagnostic, CAA, will also be used in order to increase the robustness of the assessment of CCA &amp;amp; KK. Furthermore, the present study aims to enhance knowledge of the spatial distribution of schistosomiasis in Minas Gerais province, Brazil that will assist planning of the preventive chemotherapy strategy for the national schistosomiasis control programme.</gtr:technicalSummary><gtr:potentialImpactText>The main beneficiaries of this work will be the study populations where this survey is being conducted. Neglected tropical diseases (NTDs) are a group of 17 diseases including schistosomiasis, that impact the economic potential of over billion people living under $2 per day. NTDs have an impact on the achievement of the Millennium Development Goals (MDGs). Without addressing these diseases, the broader aim of poverty alleviation is unlikely to be achieved. If prevalence levels are found to be high enough, treatment will be provided by SCI and the local Ministry of Health to ensure that Schistosomiasis is no longer a public health problem. If the burden of disease is improved in these populations the quality of life, health and economic output of such communities will greatly increase. 

The World Health Organisation will in turn benefit from the findings of this survey and whether to recommend the CCA tool as a mapping diagnostic for developing countries to create an accurate national schistosomiasis control plan. 

The Schistosomiasis Control Initiative charity will also beneift from these results in evaluating their current programs and guiding future countries in assessing the impact of treatment and mapping the disease, respectively. The research and professional skills of staff working on this project in the UK and Brazil will develop with such a project and the collaboration between the different universities and sharing of experiences and knowledge. There will be local laboratory technicians and health professionals employed in the study as well as community leaders, all of whom will gain employment as well as knowledge of schistosomiasis during the course of the study.

The realistic timescale for the benefits to start to be realised will be one month after the mapping baseline data collection in January 2016.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-01-13</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-01-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>90531</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>FAPEMIG</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>Bi lateral partnership with FAPEMIG, Federal University of Minas Gerais, Brazil</gtr:description><gtr:id>629E6CD7-4EAF-48E3-9202-D4CEFE2018AD</gtr:id><gtr:impact>A protocol has been developed</gtr:impact><gtr:outcomeId>58c6a6a91bfae1.42573089-1</gtr:outcomeId><gtr:partnerContribution>The partners in Brazil have started (in December 2016) the sensitisation of the local populations in preparation for field work collecting baseline data (scheduled for 4th April as a starting date) . Field work tools have been prepared and equipment needed has been delivered on site.</gtr:partnerContribution><gtr:piContribution>Scientific technical advice</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MR/N017722/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes><gtr:rcukProgramme><gtr:id>C11BDEA9-7D9D-4728-B6A9-31032921B328</gtr:id><gtr:text>Newton</gtr:text></gtr:rcukProgramme></gtr:rcukProgrammes></gtr:project></gtr:projectComposition></gtr:projectOverview>